TCT 2022: SYMPLICITY HTN-3 Trial Data Show Sustained Long-Term Blood Pressure Reductions With Medtronic Renal Denervation Procedure
Subjects who underwent radiofrequency renal denervation (RF RDN) with the first generation Symplicity ™ renal denervation system, had a statistically significant reduction in office and ambulatory blood pressure compared to subjects in the sham control group. The data were presented today as Late-Breaking Clinical Science at the 34th Transcatheter Cardiovascular Therapeutics (TCT) conference, the annual scientific symposium of the Cardiovascular Research Foundation, and published simultaneously in The Lancet. (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - September 18, 2022 Category: Cardiology Source Type: news

Medtronic Launches Newest Drug-Eluting Stent: The Onyx Frontier ™
The major improvement is that it employs a more deliverable system: an innovative dual-layer balloon, a lower profile for crossing, and increased catheter flexibility. These refinements point to a 16% improvement in deliverability vs. the previous generation while maintaining superior radial strength. (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - August 25, 2022 Category: Cardiology Source Type: news

New US Population Study Projects Steep Rise in Cardiovascular Diseases by 2060
Study projects substantial changes in the prevalence of CV risk factors and disease in the U.S. population by 2060, with an increasing prevalence among Black and Hispanic populations who have historically experienced poor access to quality health care. Targeted efforts toward improved screening and equitable access to quality health care in populations with the greatest growth in CV risk factors or disease would be expected to have a substantial impact to reduce future CV risk for the population overall. (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - August 1, 2022 Category: Cardiology Source Type: news

Non-Invasive FFR Gets Boost from Medtronic
FFRangio was developed by CathWorks, an Israeli company, and was approved by the US FDA in 2018, and a year later by the Ministry of Health, Labour and Welfare in Japan. The pivotal study that led to FDA approval, FAST-FFR, showed that angiography-derived FFR was highly accurate when compared with pressure-wire FFR. This week Medtronic announced that it was investing $75 million in the company, co-promoting its use, and has an option to acquire CathWorks for $585 million, once certain milestones are met. (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - July 17, 2022 Category: Cardiology Source Type: news

Two-Year Results from Onyx ONE Trial: No Difference Between Onyx DES and BioFreedom DCS
The results, consistent with the outcomes seen at one year, showed that at two years there were no differences between HBR patients on one month of DAPT who received the Onyx permanent polymer drug-eluting stent (DES), made by Medtronic, and those who received the BioFreedom polymer-free drug-coated stent (DCS), made by Biosensors. (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - June 9, 2022 Category: Cardiology Source Type: news

Late-Breaking Data Reinforce Broad Range of Patients Benefit from Abbott's Mitral and Tricuspid Heart Valve Devices
MitraClip, manufactured by Abbott Abbott today announced late-breaking data for MitraClip ™, the world's first transcatheter edge-to-edge repair (TEER) device, and TriClip™, a first-of-its kind minimally invasive tricuspid heart valve repair device. The data reinforce the capabilities of the company's structural heart solutions for both mitral and tricuspid regurgitation (MR and TR) across a broad range of patient groups battling leaky heart valves (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - June 8, 2022 Category: Cardiology Source Type: news

Renal Denervation for Controlling Hypertension Featured at EuroPCR
At this year's EuroPCR meeting in Paris, the largest European conference in the field of interventional cardiology, the topic of renal denervation (RDN) resurfaced with significant positive results from several trials across devices. The bottom line was that in these sham-controlled trials, renal denervation provided an additional therapeutic avenue for those patients who are unable to control their hypertension with lifestyle changes and medications. In all the studies presented, RDN lowered blood pressures whether the patient was on or off medications. (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - June 6, 2022 Category: Cardiology Source Type: news

Shockwave Medical and Genesis MedTech Obtain Regulatory Approval in China for Intravascular Lithotripsy
Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, and Genesis MedTech Group announced today that they have successfully obtained approval from China ’s National Medical Products Administration (NMPA) to market and sell the Shockwave IVL System with the Shockwave C2 Coronary IVL Catheters and the Shockwave M5 and S4 Peripheral IVL Catheters in China. (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - May 23, 2022 Category: Cardiology Source Type: news

Significantly Improved Results for Medtronic's Evolut TAVR seen in the Optimize PRO Study
At this year's EuroPCR meeting, the interim results of the Optimize PRO study of Medtronic's Evolut ™ PRO and PRO+ TAVR systems in 400 patients were presented as a Hotline Trial: permanent pacemaker rates dropped to single digits (9.2%) and the number of patients with moderate or severe paravalvular leak (PVL) was zero (78% of patients had no or only trace PVL). Moreover, the median length of ho spital stay was one day. (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - May 22, 2022 Category: Cardiology Source Type: news

Intravascular Lithotripsy May Emerge as a First-Line Therapy for Calcified Lesions in Women
“Given the established safety profile of IVL and the high rates of acute and long-term adverse events in women undergoing PCI, with or without atheroablation of calcified lesions, coronary IVL is an attractive treatment option for optimizing outcomes in our female patients,” said Alexandra Lansk y, MD, FACC, FAHA, FSCAI, FESC, Professor of Medicine (Cardiology); Director of Yale Cardiovascular Clinical Research Program, Yale University School of Medicine, New Haven, Conn. “While this is the first one-year analysis of its kind for coronary IVL, the sustained benefit in MACE at one year sug gests that IVL should be con...
Source: News from Angioplasty.Org - May 20, 2022 Category: Cardiology Source Type: news

ITAL-neo Registry: Boston Scientific's ACURATE neo2 Valve Significantly Reduces Paravalvular Leak (PVL) from 1st Generation Device
The first generation TAVR exhibited a not insignificant moderate or greater paravalvular leak. By adding a taller external skirt for the newer device, the PVL was reduced from 11.2% down to 3.5%. (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - May 19, 2022 Category: Cardiology Source Type: news

Medtronic Receives FDA Approval for Latest Generation Drug-Eluting Coronary Stent System
Design changes include increased catheter flexibility, an innovative dual-layer balloon technology and a lower crossing profile, leading to a 16% improvement in deliverability vs. the previous generation Resolute Onyx DES. Onyx Frontier offers a broad size matrix to treat more patients and is the only 2.0 mm DES available in the United States (similar to Resolute Onyx). Further, Onyx Frontier continues to provide 4.50-5.00 mm sizes that can be expanded to 6.00 mm - specifically designed to support extra-large vessels. (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - May 13, 2022 Category: Cardiology Source Type: news

Society for Vascular Medicine Elects Dr. Herb Aronow as New President
"It is an honor to serve as SVM's next President and I look forward to working alongside the Board of Trustees and other Society leaders to advance the vascular medicine discipline and the care of vascular patients," Aronow said. "In collaboration with other vascular organizations, I plan to broaden our efforts around vascular education, research and quality." (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - June 18, 2021 Category: Cardiology Source Type: news

Complete Two-Year Data Confirms That Medtronic's Evolut TAVR System Is Non-Inferior to Open Heart Surgery in Low Risk Patients
Confirming the preliminary data that was previously presented at the 2019 Scientific Session of the American College of Cardiology, the complete data from over 1,400 patients enrolled in the Evolut Low Risk Trial was presented (virtually) at this year's EuroPCR meeting by John K Forrest, MD, FACC, FSCAI. The result: the primary endpoint of all-cause mortality or disabling stroke at two years was 4.3% for TAVR versus 6.3% for surgery (p (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - June 1, 2021 Category: Cardiology Source Type: news

Medtronic Announces CE Mark of Evolut ™ PRO+ TAVI System for Treatment of Symptomatic Severe Aortic Stenosis Patients in Europe
The system includes 4 valve sizes with an external pericardial tissue wrap that provides advanced sealing for the largest annular range (for self-expanding TAVI technology) on the market. The approval follows a recent indication expansion for the Evolut platform in Europe for patients with severe aortic stenosis who are at a low risk of surgical mortality and patients with bicuspid aortic valves who are at intermediate, high and extreme risk of surgical mortality. (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - May 3, 2021 Category: Cardiology Source Type: news